Every year four million baby teeth fall out, and 1.4 million wisdom teeth are pulled out of our collective mouth. Until recently, the only entity really interested in all those teeth was the tooth fairy. But all that changed in the year 2000, with the discovery that dental pulp contains adult stem cells. In the not-too-distant future, those stem cells might be used for growing new islet cells to cure diabetes. The problem is, how to keep the teeth nice and fresh until that hoped-for day. That's where Provia Laboratories comes in, with their Store-A-Tooth service.
INDIANAPOLIS and NEW YORK - Eli Lilly and Company and the Juvenile Diabetes Research Foundation (JDRF) today announced that they have signed an agreement to fund early-stage research that could enable patients with type 1 diabetes to regenerate insulin-producing cells destroyed by the disease.
(Reuters) - Stem cells can be transformed into the pancreatic cells needed to treat diabetes and into complex layers of intestinal tissue, scientists demonstrated in two experiments reported on Sunday.
"The objective of this clinical trial (research study) is to determine if the medications can rescue the few beta cells that remain soon after the diagnosis of type 1 diabetes; and whether new beta cells can even be regenerated," commented Alex Rabinovitch, MD, Principal Investigator of the trial and Associate Director of The Sanford Project. "The investigational combinations of these medications could possibly allow patients to decrease or no longer need to inject insulin to keep their blood levels under proper control."
Over 80 years ago, famed diabetologist Elliot Joslin said about the treatment of patients with type 1 diabetes: "Ketoacidosis may kill a patient, but frequent hypoglycemic reactions will ruin him." Unfortunately, hypoglycemia continues to be the most difficult problem facing most patients, families, and caregivers who deal with the management of type 1 diabetes on a daily basis. Frequent hypoglycemia episodes not only can "ruin," or adversely impact the quality of life for patients, but also, when severe, can cause seizures, coma, and even death.
Dr. Richard Hays announced today that he is now recruiting children with newly diagnosed type 1 diabetes for Protégé Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protégé, has completed enrollment of more than 530 subjects with type 1 diabetes. There is currently no approved therapy to slow the progression of type 1 diabetes.
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.